摘要
Abstract
Objective To investigate the clinical efficacy of trimetazidine for ischemic cardiomyopathy heart failure and its effect on car-diac function and heart rate variability. Methods 76 cases of patients with ischemic cardiomyopathy heart failure were randomly divided into two groups. 38 cases in the control group were treated with conventional anti heart failure treatment, while the observation group of 38 patients used Trimetazidine Hydrochloride Tablets on the basis of the conventional treatment. The clinical efficacy and the changes of heart function and heart rate variability index before and after treatment of the two groups were compared. Results The total effective rate of the observation group was 94. 74%, which was significantly higher than 76. 32% of the control group, the difference was statisti-cally significant (χ2=9. 76, P < 0. 05 ) . After treatment, the LVEDd, LVEDd of the observation group were ( 58. 26 ± 5. 67 ) mm and ( 44. 21 ± 4. 83 ) mm, which were significantly lower than the control group ( t=6. 32, 6. 76, P < 0. 05 ) , and LVEF and SU were ( 46. 21 ± 5. 07 )% and ( 72. 43 ± 6. 87 ) mL, which were significantly higher than the control group ( t=6. 56, 7. 04, P < 0. 05 ); the SDNN, SDANN, RMSSD and PNN50 of the observation group were ( 125. 64 ± 17. 26 ) ms, ( 113. 47 ± 14. 75 ) ms, ( 20. 11 ± 5. 66 )%, ( 46. 47 ± 10. 36 ) ms, which were significantly increased compared with the control group, the difference was statistically significant ( t=8. 04, 7. 59, 7. 44, 7. 81, P < 0. 05 ) . Conclusion The clinical efficacy of trimetazidine for heart failure in ischemic cardiomyopathy is significant, the heart function and heart rate variability index improvement is more obvious, and it is worthy of clinical promotion.关键词
曲美他嗪/缺血性心肌病/心力衰竭/心率变异性Key words
trimetazidine/ischemic cardiomyopathy/heart failure/heart rate variability分类
医药卫生
